6-(4-[1,1-dimethyl-2-(2-oxo-1-piperidinyl)ethyl]phenyl)-1-(4-methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 6-(4-[1,1-dimethyl-2-(2-oxo-1-piperidinyl)ethyl]phenyl)-1-(4-methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
• 英文别名: 6-{4-[1,1-dimethyl-2-(2-oxo-1-piperidinyl)ethyl]phenyl}-1-(4-methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide；1-(4-methoxyphenyl)-6-[4-[2-methyl-1-(2-oxopiperidin-1-yl)propan-2-yl]phenyl]-7-oxo-4,5-dihydropyrazolo[3,4-c]pyridine-3-carboxamide
• 化学式: C₂₉H₃₃N₅O₄
• 分子量: 515.612
• InChiKey: BCRNMWOVSSOCIE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  38
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  111
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  1-(4-甲氧基苯基)-7-氧代-4,5,6,7-四氢-1H-吡唑并[3,4-c]吡啶-3-羧酸乙酯 在 盐酸 、 copper(l) iodide 、 1,10-菲罗啉 、 palladium 10% on activated carbon 、 potassium tert-butylate 、 氨 、 氢气 、 potassium carbonate 、 乙二醇 、 三乙胺 作用下， 以 四氢呋喃 、 二甲基亚砜 为溶剂， 生成 6-(4-[1,1-dimethyl-2-(2-oxo-1-piperidinyl)ethyl]phenyl)-1-(4-methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
  参考文献：
  名称：

  Orally bioavailable factor Xa inhibitors containing alpha-substituted gem-dimethyl P4 moieties

  摘要：

  In an effort to identify a potential back-up to apixaban (Eliquie (R)), we explored a series of diversified P4 moieties. Several analogs with substituted gem-dimethyl moieties replacing the terminal lactam of apixaban were identified which demonstrated potent FXa binding affinity (FXa K-i), good human plasma anticoagulant activity (PT EC2x), cell permeability, and oral bioavailability. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.05.101

文献信息

• [EN] 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS<br/>[FR] DERIVES CYCLOALKYLES 1,1-DISUBSTITUES UTILISES EN TANT QU'INHIBITEURS DU FACTEUR XA
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2003099276A1

  公开（公告）日：2003-12-04

  The present application describes 1,1-disubstituted cycloalkyl compounds and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.

  本申请描述了1,1-二取代环烷基化合物及其衍生物，或其药用可接受的盐形式，这些化合物对于Xa因子的抑制剂具有用处。
• 1,1-Disubstituted cycloalkyl derivatives as factor Xa inhibitors
  申请人：——

  公开号：US20040254158A1

  公开（公告）日：2004-12-16

  The present application describes 1,1-disubstituted cycloalkyl compounds and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.

  本申请描述了1,1-二取代环烷基化合物及其衍生物，或其药学上可接受的盐形式，这些化合物可用作因子Xa的抑制剂。
• 1, 1-disubstituted cycloalkyl derivatives as factor Xa inhibitors
  申请人：Bristol-Myers Squibb Company

  公开号：US07312214B2

  公开（公告）日：2007-12-25

  The present application describes 1,1-disubstituted cycloalkyl compounds and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.

  本申请描述了1,1-二取代环烷基化合物及其衍生物或其药学上可接受的盐形式，它们可用作凝血因子Xa的抑制剂。
• US7312214B2
  申请人：——

  公开号：US7312214B2

  公开（公告）日：2007-12-25
• Orally bioavailable factor Xa inhibitors containing alpha-substituted gem-dimethyl P4 moieties
  作者：Michael J. Orwat、Jennifer X. Qiao、Kan He、Alan R. Rendina、Joseph M. Luettgen、Karen A. Rossi、Baomin Xin、Robert M. Knabb、Ruth R. Wexler、Patrick Y.S. Lam、Donald J.P. Pinto

  DOI：10.1016/j.bmcl.2014.05.101

  日期：2014.8

  In an effort to identify a potential back-up to apixaban (Eliquie (R)), we explored a series of diversified P4 moieties. Several analogs with substituted gem-dimethyl moieties replacing the terminal lactam of apixaban were identified which demonstrated potent FXa binding affinity (FXa K-i), good human plasma anticoagulant activity (PT EC2x), cell permeability, and oral bioavailability. (C) 2014 Elsevier Ltd. All rights reserved.